Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Yaseen Aleatany

Rheumatology Columbus, GA Medical Doctor

NPI 1326569815 CMS profile 4090718

2000 10Th Ave Ste 225, Columbus, GA 31901

Open in the dashboard

General payments

$3,353

150 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yaseen Aleatany of Columbus, GA is reported in the CMS Open Payments database as having received $3,353 across 150 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,093 49
2024 General $1,148 50
2023 General $874 40
2022 General $238 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yaseen Aleatany
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Yaseen Aleatany were reported at $1,093. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Yaseen Aleatany Rheumatology median Middle half National median
2019 $0 $744 $153–$2,687 $163
2020 $0 $462 $98–$2,027 $114
2021 $0 $531 $101–$2,153 $132
2022 $238 $627 $125–$2,303 $149
2023 $874 $741 $145–$2,524 $160
2024 $1,148 $830 $166–$2,660 $164
2025 $1,093 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $607 29 payments
  2. Novartis Pharmaceuticals Corporation $597 28 payments
  3. Amgen Inc. $377 19 payments
  4. UCB, Inc. $338 18 payments
  5. Mallinckrodt Hospital Products Inc. $309 11 payments
  6. Horizon Therapeutics plc $247 8 payments
  7. Janssen Biotech, Inc. $203 6 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $167 7 payments
  9. GlaxoSmithKline, LLC. $155 7 payments
  10. Lilly USA, LLC $125 6 payments
  11. Other $228 11 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $3,193 148 payments
  2. Education $160 2 payments
Products named General payments · program years 2022–2025
  1. COSENTYX $523 25 payments
  2. RINVOQ $453 21 payments
  3. ACTHAR $309 11 payments
  4. KRYSTEXXA Inflammation/Rare Disease $254 13 payments
  5. KRYSTEXXA Krystexxa $221 7 payments
  6. TREMFYA $203 6 payments
  7. Cimzia $173 10 payments
  8. Bimzelx $165 8 payments
  9. BENLYSTA $155 7 payments
  10. TALTZ $125 6 payments
  11. Other $908 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,954

Median for Rheumatology: 1,511

Drug cost

$3,089,698

Median for Rheumatology: $1,139,948

Branded share of claims

36.1%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 123 $899,363
Krystexxa Pegloticase Brand 22 $628,343
Humira(Cf) Pen Adalimumab Brand 78 $600,827
Rinvoq Upadacitinib Brand 62 $453,709
Orencia Clickject Abatacept Brand 31 $172,688
Kevzara Sarilumab Brand 39 $168,227
Benlysta Belimumab Brand 25 $122,843
Hydroxychloroquine Sulfate Generic 375 $12,337
Mycophenolate Mofetil Generic 35 $11,878
Leflunomide Generic 116 $6,699

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$39,382

Of which drugs: $89

Medicare patients

186

Average age 71

Services billed

591

140 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Chronic kidney disease 39%
Diabetes 31%
Depression 26%
Ischemic heart disease 24%
Osteoporosis 19%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 118 $89

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
COSENTYX
  • Novartis Pharmaceuticals Corporation $262
$262 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $150
$150 — —
KRYSTEXXA
  • Amgen Inc. $109
$109 22 —
TREMFYA
  • Janssen Biotech, Inc. $91
$91 — —
BENLYSTA
  • GlaxoSmithKline, LLC. $84
$84 25 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

150 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record